Literature DB >> 14991935

Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.

Yuksel Gumurdulu1, Ender Serin, Birol Ozer, Fazilet Kayaselcuk, Kursat Ozsahin, Arif Mansur Cosar, Murat Gursoy, Gurden Gur, Ugur Yilmaz, Sedat Boyacioglu.   

Abstract

AIM: The eradication rate of Helicobacter pylori (H pylori) shows variation among countries and regimens of treatment. We aimed to study the eradication rates of different regimens in our region and some factors affecting the rate of eradication.
METHODS: One hundred and sixty-four H pylori positive patients (68 males, 96 females; mean age: 48+/-12 years) with duodenal or gastric ulcer without a smoking history were included in the study. The patients were divided into three groups according to the treatment regimens. Omeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g were given twice daily for 1 week (Group I) and 2 weeks (Group II). Patients in Group III received bismuth subsitrate 300 mg, tetracyline 500 mg and metronidazole 500 mg four times daily in addition to Omeprazole 20 mg twice daily. Two biopsies each before and after treatment were obtained from antrum and corpus, and histopathologically evaluated. Eradication was assumed to be successful if no H pylorus was detected from four biopsy specimens taken after treatment. The effects of factors like age, sex, H pylori density on antrum and corpus before treatment, the total H pylori density, and the inflammation scores on the rate of H pylori eradication were evaluated.
RESULTS: The overall eradication rate was 42%. The rates in groups II and III were statistically higher than that in group I (P<0.05). The rates of eradication were 24.5%, 40.7% and 61.5% in groups I, II and III, respectively. The eradication rate was negatively related to either corpus H pylori density or total H pylori density (P<0.05). The median age was older in the group in which the eradication failed in comparison to that with successful eradication (55 yr vs 39 yr, P<0.001). No correlation between sex and H pylori eradication was found.
CONCLUSION: Our rates of eradication were significantly lower when compared to those reported in literature. We believe that advanced age and high H pylori density are negative predictive factors for the rate of H pylori eradication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991935      PMCID: PMC4716906          DOI: 10.3748/wjg.v10.i5.668

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Treatment after failure: the problem of "non-responders".

Authors:  J Q Huang; R H Hunt
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

2.  pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism.

Authors:  R H Hunt
Journal:  Am J Gastroenterol       Date:  1993-04       Impact factor: 10.864

3.  A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer.

Authors:  A Leodolter; M Kulig; H Brasch; W Meyer-Sabellek; S N Willich; P Malfertheiner
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

4.  Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.

Authors:  J J Kim; R Reddy; M Lee; J G Kim; F A El-Zaatari; M S Osato; D Y Graham; D H Kwon
Journal:  J Antimicrob Chemother       Date:  2001-04       Impact factor: 5.790

Review 5.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

6.  Comparison of seven and fourteen days of lansoprazole, clarithromycin, and amoxicillin therapy for eradication of Helicobacter pylori: a report from India.

Authors:  D K Bhasin; B C Sharma; P Ray; C M Pathak; K Singh
Journal:  Helicobacter       Date:  2000-06       Impact factor: 5.753

7.  Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicillin, and clarithromycin.

Authors:  S D Georgopoulos; S D Ladas; S Karatapanis; A Mentis; C Spiliadi; V Artikis; S A Raptis
Journal:  Dig Dis Sci       Date:  2000-01       Impact factor: 3.199

8.  Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication.

Authors:  H B Yang; B S Sheu; I J Su; C H Chien; X Z Lin
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

Review 9.  Antimicrobial resistance in Helicobacter pylori: a global overview.

Authors:  Y Glupczynski
Journal:  Acta Gastroenterol Belg       Date:  1998 Jul-Sep       Impact factor: 1.316

Review 10.  Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.

Authors:  A H Soll
Journal:  JAMA       Date:  1996-02-28       Impact factor: 56.272

View more
  42 in total

1.  Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.

Authors:  Li-Hui Wang; Hong Cheng; Fu-Lian Hu; Jiang Li
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Sequential Therapy for Helicobacter Pylori Eradication: The Time is Now!

Authors:  Dino Vaira; Angelo Zullo; Cesare Hassan; Giulia Fiorini; Nimish Vakil
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 3.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

4.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

5.  The oligo-acyl lysyl antimicrobial peptide C₁₂K-2β₁₂ exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori.

Authors:  Morris O Makobongo; Hanan Gancz; Beth M Carpenter; Dennis P McDaniel; D Scott Merrell
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

6.  Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial.

Authors:  Ping-I Hsu; Feng-Woei Tsai; Sung-Shuo Kao; Wen-Hung Hsu; Jin-Shiung Cheng; Nan-Jing Peng; Kuo-Wang Tsai; Huang-Ming Hu; Yao-Kuang Wang; Seng-Kee Chuah; Angela Chen; Deng-Chyang Wu
Journal:  Am J Gastroenterol       Date:  2017-07-18       Impact factor: 10.864

7.  First-line therapy in Helicobacter pylori eradication therapy: experience of a surgical clinic.

Authors:  Gökhan Selçuk Özbalcı; Saim Savaş Yürüker; İsmail Alper Tarım; Hamza Çınar; Ayfer Kamalı Polat; Aysu Başak Özbalcı; Kağan Karabulut; Kenan Erzurumlu
Journal:  Ulus Cerrahi Derg       Date:  2014-09-01

8.  Azithromycin in one week quadruple therapy for H pylori eradication in Iran.

Authors:  Shahrokh Mousavi; Jafar Toussy; Siamak Yaghmaie; Mehrdad Zahmatkesh
Journal:  World J Gastroenterol       Date:  2006-07-28       Impact factor: 5.742

9.  Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori.

Authors:  Hong Cheng; Fu-Lian Hu
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

10.  Advances in gastric cancer prevention.

Authors:  Antonio Giordano; Letizia Cito
Journal:  World J Clin Oncol       Date:  2012-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.